



GLOBE BIOTECH LIMITED

Address: Plot No. 3/Ka (New), Tejgaon Industrial Area, Dhaka-1208, Bangladesh.
Phone: +880 9609 777700, Email: info@globe-biotech.com, Website: www.globe-biotech.com

First in Bangladesh

Press release about the discovery of vaccine for "COVID-19"

Dated: Dhaka
01/07/2020

To
The Respected Journalists
Bangladesh

Subject: Discovery of the first "COVID-19" vaccine in Bangladesh.

Dear Correspondent,

We would like to inform you that Globe Biotech Limited, a sister concern of Globe Pharmaceuticals Group of Companies Limited started its journey through establishing a state-of-the-art facility to discover, develop and manufacture biologics, novel drugs and biosimilars for the treatment of cancer, arthritis, anemia, hypertension, auto immune diseases and other incurable diseases since 2015. Scientists at the organization have already been able to produce biosimilars for a number of incurable diseases, which are waiting for ethical approval of clinical trial from Bangladesh Medical Research Council (BMRC).

People around the world are devastated by the current outbreak of COVID-19. On national and international needs, we started research activities related to the discovery and development of COVID-19, "detection kit, vaccine and biosimilar". Under the supervision of CEO Dr. Kakon Nag and COO Dr. Naznin Sultana, we have successfully achieved the discovery of Covid-19 vaccine.

According to the NCBI Virus database, 5,743 complete genome sequences have been submitted worldwide till June 30, 2020 of which 76 have been submitted from Bangladesh. By analysis of all of these sequences through bioinformatics tools, we have confirmed our vaccine targets. We expect this vaccine logically will be more effective in this geographic region. We have already submitted the complete coding sequence of the vaccine target to the NCBI Virus database in the United States which has already been published by NCBI (accession number: MT676411). After extensive analysis of the vaccine discovered in our facility, our vaccine is satisfactorily able to produce the target neutralizing antibodies in laboratory animal model.

In this context, we are working to launch a clinical trial to assess the safety and efficacy of this vaccine. For the safety and efficacy analysis, we are earnestly anticipating support from government as well as media.

Best regards,

Md. Harunur Rashid
Chairman

Globe Biotech Limited
Globe Pharmaceuticals Group of Companies Ltd.